| Market Cap | 44.04M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -11.78M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -98.00% |
| Sales | 10.38k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -98.00% |
| Dividend | N/A | Price/Book | 9.27 | EPS next 5Y | - | 52W High Chg | -99.00% |
| Recommedations | 2.00 | Quick Ratio | 18.34 | Shares Outstanding | 431.73M | 52W Low Chg | 7.00% |
| Insider Own | 5.01% | ROA | -55.17% | Shares Float | 409.47M | Beta | 1.04 |
| Inst Own | 0.02% | ROE | -364.81% | Shares Shorted/Prior | -/- | Price | 0.10 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 3,129 | Target Price | - |
| Oper. Margin | -101,421.71% | Earnings Date | May 12 | Volume | 685,017 | Change | -0.58% |
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
